JAX Taps Finance Veteran to Fuel New Era of Biomedical Discovery

BAR HARBOR, Maine – April 13, 2026 – The Jackson Laboratory (JAX), a global leader in genomic medicine, has appointed Steven Holstein as its new Senior Vice President of External Affairs, a strategic move signaling a significant intensification of its mission to reshape biomedical research. The appointment comes as JAX pivots toward a new, highly integrated, platform-driven model designed to dramatically accelerate the journey from scientific insight to breakthrough therapies.

Holstein, a veteran with over two decades of leadership experience spanning financial services, healthcare, and life sciences, is tasked with orchestrating a unified enterprise strategy across advancement, communications, marketing, and government affairs. His role is central to a bold vision: building the network of partnerships, capital, and global engagement necessary to power JAX's next-generation research engine.

"JAX is advancing a more integrated, platform-driven approach in biomedical research, bringing together multiple models of human biology to accelerate translation of discoveries into therapies," said Lon Cardon, Ph.D., FMedSci, president and CEO of JAX, in a statement. "Realizing the full impact of our vision requires strong alignment across partnerships, capital, and global engagement. Steven brings the leadership to connect our science to the relationships and resources needed to build that momentum."

A New Blueprint for Discovery

The strategy Holstein is set to champion supports a fundamental shift in how JAX approaches science. The institution is moving beyond traditional, siloed research methods to deploy what it calls an "integrated discovery engine." This platform-driven approach combines JAX's world-renowned expertise in mouse genetics and preclinical modeling with two other powerful pillars: advanced stem cell science and AI-powered data analysis.

This new model was significantly enhanced by JAX's 2025 acquisition of the New York Stem Cell Foundation (NYSCF). The move integrated NYSCF's pioneering stem cell technologies and automation capabilities, including the NYSCF Global Stem Cell Array®, a robotic platform for conducting large-scale, highly reproducible stem cell research. By pairing this technology with its sophisticated mouse models, JAX can now test predictions about disease and treatment response on diverse human cells before validating those findings in a whole-organism setting, creating a more predictive and efficient research cycle.

This torrent of data from mouse and cell systems is then analyzed using advanced AI and machine learning tools, allowing scientists to uncover complex disease mechanisms and test potential therapies with greater precision and speed. The goal is to overcome the slow, costly, and often uncertain nature of translational science, making the path to new medicines for diseases like Alzheimer's, cancer, and diabetes more direct and successful.

From Finance to the Frontier of Science

To power this ambitious scientific vision, JAX has turned to a leader with a uniquely blended background. Holstein's career is not that of a traditional research administrator. He has held senior roles at financial giants like MassMutual, Guardian, and Fidelity Investments, leading enterprise-level marketing and growth strategies.

More recently, his role as managing director at Outcome Capital saw him directly advising life science and healthcare innovators on capital formation and strategic partnerships. This experience at the intersection of science and finance makes him a key asset for JAX. He is tasked with translating the institution's complex scientific value into a compelling case for investors, philanthropic donors, and corporate partners.

This appointment reflects a broader trend in the nonprofit research world, where securing sustainable and diverse funding streams has become as critical as the science itself. With federal funding becoming increasingly competitive, institutions like JAX are actively seeking leaders who can navigate the worlds of venture capital, industry collaboration, and major philanthropy to secure the resources needed for large-scale, long-term projects.

"JAX plays a unique role in the biomedical ecosystem by developing and integrating the models, data, and platforms that enable more predictive, scalable science," Holstein stated. "The opportunity now is to connect that scientific foundation more directly to the partnerships, capital, and global engagement required to accelerate discovery and deliver real-world impact."

Building a Global Biomedical Hub

Holstein's appointment is the latest in a series of strategic moves designed to position JAX not just as a research institution, but as a central hub and catalyst in the global biomedical community. The organization is actively extending its platform's capabilities beyond its own labs and into a worldwide network of collaborators.

A prime example is the five-year strategic research collaboration announced in February 2026 between the JAX-NYSCF Collaborative and pharmaceutical giant GSK. The partnership focuses on developing more predictive human cellular models of neurodegenerative diseases, combining GSK's drug discovery expertise with JAX's integrated platform. This collaboration validates JAX's strategy, demonstrating that its unique combination of mouse, cell, and AI models is a powerful draw for industry players seeking to de-risk and accelerate their own research and development pipelines.

By creating a scalable and accessible platform, JAX aims to empower researchers everywhere, from academic institutions to biotech startups, helping them move more quickly from insight to impact. Holstein's mandate involves expanding this network, reinforcing JAX's role as a convener that can bring together the right partners to tackle the most complex challenges in human health. His leadership in external affairs will be crucial for forging the alliances that transform scientific potential into tangible medical breakthroughs on a global scale.